The Company plans to submit the fourth and final module of the Pre-Market Approval application to the FDA. Topline data were announced from the AUDACITY trial evaluating the Allurion Gastric ...

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

In Malaysia, cases of overweight and obesity are now increasing at an alarming rate. Photo by Jeslyn Teh. The Allurion intragastric balloon (IGB) is inserted through the mouth into the patient's ...

Growing demand for weight-loss solutions has catapulted pharmaceutical firms like Eli Lilly (LLY) and Novo Nordisk (NVO) into ...

Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...

The rate of serious adverse events in Allurion Balloon subjects in the AUDACITY trial was 3.1%, the lowest reported in a pivotal FDA trial for a liquid-filled intragastric balloon indicated for ...

Allurion (ALUR) stock soared 70% after the company announced it is planning to conduct a clinical study of its gastric balloon weight-loss product in combination with GLP-1 drugs.

The rate of serious adverse events in Allurion Balloon subjects in the AUDACITY trial was 3.1%, the lowest reported in a pivotal FDA trial for a liquid-filled intragastric balloon indicated for ...

The Allurion intragastric balloon (IGB) is inserted through the mouth into the patient's stomach endoscopically before being expanded with 550 milliliters of water. “Over the past decade, demand for ...

If you can’t beat them then join them. In a bid to combat weakening financial performance, Allurion has revealed plans to initiate a clinical study evaluating its weight loss programme in ...